劲方医药登陆香港联交所，华兴资本担任联席账簿管理人及联席牵头经办人

Group 1 - The core viewpoint of the article is that Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd. has successfully listed on the Hong Kong Stock Exchange with a base issuance scale of approximately $230 million, potentially increasing to $270 million with full exercise of the over-allotment option [1][2] - Jinfang Pharmaceutical is a biopharmaceutical company with a global vision and operations, having already received approval for its first innovative drug. The company focuses on innovation and advanced treatment methods to meet various medical needs [1] - As of September 2, the company has established a competitive and innovative product pipeline consisting of eight candidate products, five of which are in clinical development. The pipeline primarily targets treatments related to the RAS family of genes [1] Group 2 - One of the core products, GFH925 (fulzerasib, marketed as Daberu®), has been commercially approved in China for the treatment of advanced non-small cell lung cancer (NSCLC). The company is also exploring treatments for autoimmune and inflammatory diseases, as well as other cancer-related therapies [1] - Huaxing Capital played a significant role in the underwriting process, successfully introducing several internationally renowned long-term funds as cornerstone investors, reflecting strong market recognition of the company's R&D capabilities and growth prospects [2] - The president of Huaxing International expressed pride in supporting Jinfang Pharmaceutical's listing, highlighting the company's leading R&D strength and clear global strategy, which positions it as an excellent representative of Chinese innovative pharmaceutical companies [2]